

# Eric Santoni-Rugiu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3488641/publications.pdf>

Version: 2024-02-01

96  
papers

3,205  
citations

126907

33  
h-index

161849

54  
g-index

100  
all docs

100  
docs citations

100  
times ranked

4999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
2	Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. <i>Clinical Lung Cancer</i> , 2021, 22, e528-e532.	2.6	8
3	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021, 53, 446-453.	0.6	25
4	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 989-999.	0.7	12
5	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. <i>Cancer Discovery</i> , 2021, 11, 2456-2473.	9.4	74
6	Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre – A National Danish Cohort. <i>Frontiers in Endocrinology</i> , 2021, 12, 727970.	3.5	5
7	The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11452.	4.1	3
8	Functional Proteomic Profiling of Triple-Negative Breast Cancer. <i>Cells</i> , 2021, 10, 2768.	4.1	10
9	Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12868.	4.1	2
10	Treatment Algorithm for Advanced ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e156-e157.	1.1	2
11	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2847.	4.1	25
12	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.	3.7	124
13	High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. <i>Npj Genomic Medicine</i> , 2019, 4, 13.	3.8	63
14	Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins. <i>Journal of Cell Biology</i> , 2019, 218, 333-349.	5.2	14
15	Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2019, 127, 69-75.	2.0	19
16	Copenhagen Prospective Personalized Oncology (CoPPO) – Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1239-1247.	7.0	59
17	Application of cell-free DNA for genomic tumor profiling: a feasibility study. <i>Oncotarget</i> , 2019, 10, 1388-1398.	1.8	13
18	Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim). <i>Respiratory Medicine Case Reports</i> , 2018, 23, 167-169.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. <i>Oncotarget</i> , 2018, 9, 26195-26208.	1.8	35
20	Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC) validation in two independent cohorts. <i>PLoS ONE</i> , 2018, 13, e0194609.	2.5	9
21	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	1.8	15
22	Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. <i>Lung Cancer</i> , 2017, 113, 14-17.	2.0	20
23	CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1 Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2017, 153, 1662-1673.e10.	1.3	86
24	P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2203.	1.1	0
25	NSCLC multiplex IHC diagnosis of small biopsies. <i>Annals of Oncology</i> , 2016, 27, vi405.	1.2	0
26	NSCLC - multiplex immunohistochemical staining for diagnosis in small biopsies. <i>European Journal of Cancer</i> , 2016, 61, S191-S192.	2.8	0
27	Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23256-e23256.	1.6	0
28	Prospective blinded evaluation predicting efficacy of adjuvant cisplatin and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20007-e20007.	1.6	0
29	Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11531-11531.	1.6	0
30	Use of TUBB3 for patient stratification and prognosis in lung cancer. <i>Lung Cancer Management</i> , 2015, 4, 97-110.	1.5	4
31	Molecular imaging in Libman-Sacks endocarditis. <i>Infectious Diseases</i> , 2015, 47, 263-266.	2.8	15
32	Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e18502-e18502.	1.6	0
33	Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. <i>Anticancer Research</i> , 2015, 35, 6223-9.	1.1	30
34	High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. <i>Anticancer Research</i> , 2015, 35, 6731-8.	1.1	3
35	Personalized oncology: genomic screening in phase 1. <i>Apmis</i> , 2014, 122, 723-733.	2.0	18
36	Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small cell lung cancer. <i>Histopathology</i> , 2014, 64, 412-420.	2.9	3

#	ARTICLE	IF	CITATIONS
37	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2014, 5, 621.	2.3	8
38	Prdm5 suppresses ApcMin-driven intestinal adenomas and regulates monoacylglycerol lipase expression. <i>Oncogene</i> , 2014, 33, 3342-3350.	5.9	25
39	Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 131-137.	2.3	3
40	Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 645-652.	2.5	1
41	Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 43-51.	2.3	5
42	Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 418-430.	2.8	57
43	Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11097-11097.	1.6	1
44	Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 2991-6.	1.1	10
45	Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat Tj ETQq1 1 0.784314 rgBT /Ove adenocarcinoma patient with acquired resistance to crizotinib: a case report. <i>BMC Research Notes</i> , 2013, 6, 489.	1.4	39
46	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. <i>Annals of Oncology</i> , 2013, 24, 309-314.	1.2	18
47	Intratour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 2494-2503.	2.8	28
48	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 83-90.	2.0	33
49	Loss of miR-10a Activates Lpo and Collaborates with Activated Wnt Signaling in Inducing Intestinal Neoplasia in Female Mice. <i>PLoS Genetics</i> , 2013, 9, e1003913.	3.5	51
50	Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 152-160.	1.1	21
51	Abstract 3556: Diagnostic potential of microRNAs (miRs) in malignant pleural mesothelioma (MPM).. , 2013, , .		0
52	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. <i>Annals of Oncology</i> , 2012, 23, 2034-2042.	1.2	122
53	Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival. <i>Journal of Thoracic Oncology</i> , 2012, 7, 249-256.	1.1	32
54	RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. <i>Lung Cancer</i> , 2012, 75, 306-312.	2.0	43

#	ARTICLE	IF	CITATIONS
55	A biomarker profile for predicting efficacy of cisplatin+vinorelbine therapy in malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 743-754.	2.3	20
56	Prognostic and Predictive Impact Of KI-67 Index in Neo-Adjuvant Chemotherapy Before Surgery in Non-Small Cell Lung Cancer. <i>Annals of Oncology</i> , 2012, 23, ix80.	1.2	0
57	Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma. <i>International Journal of Cancer</i> , 2012, 130, 2734-2739.	5.1	15
58	Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2012, 131, E329-36.	5.1	41
59	The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. <i>Histopathology</i> , 2012, 60, E96-105.	2.9	18
60	Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?. <i>Apmis</i> , 2012, 120, 767-769.	2.0	11
61	No Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39646.	2.5	27
62	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomized in a chemotherapy phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10617-10617.	1.6	0
63	PP 88 C4.4A as a biomarker for poor prognosis in non-small cell lung cancer patients with adenocarcinomas. <i>European Journal of Cancer</i> , 2011, 47, S20.	2.8	0
64	The level of claudin-7 is reduced as an early event in colorectal carcinogenesis. <i>BMC Cancer</i> , 2011, 11, 65.	2.6	42
65	MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma. <i>Cancer Research</i> , 2011, 71, 4226-4235.	0.9	62
66	The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2919-2933.	7.0	118
67	Class III $\beta$ -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial. <i>Clinical Cancer Research</i> , 2011, 17, 5205-5214.	7.0	41
68	Lipocalin 2 is protective against E. coli pneumonia. <i>Respiratory Research</i> , 2010, 11, 96.	3.6	73
69	Ossifying thymoma associated with refractory myasthenia gravis. <i>Apmis</i> , 2010, 118, 334-336.	2.0	3
70	Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin (Vitamin D) Tj ETQq0 0 0,rgBT /Overlock 10 Tt	2.9	8
71	ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. <i>Annals of Oncology</i> , 2010, 21, 1817-1824.	1.2	62
72	ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. <i>European Journal of Cancer</i> , 2010, 46, 1554-1562.	2.8	23

#	ARTICLE	IF	CITATIONS
73	Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. <i>Acta Radiologica</i> , 2007, 48, 145-149.	1.1	13
74	Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell-mediated liver regeneration. <i>Hepatology</i> , 2007, 45, 1462-1470.	7.3	106
75	Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS. <i>Oncogene</i> , 2005, 24, 780-789.	5.9	38
76	Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion. <i>Apmis</i> , 2005, 113, 876-902.	2.0	104
77	Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. <i>Oncogene</i> , 2004, 23, 3670-3680.	5.9	59
78	Transit-Amplifying Ductular (Oval) Cells and Their Hepatocytic Progeny Are Characterized by a Novel and Distinctive Expression of Delta-Like Protein/Preadipocyte Factor 1/Fetal Antigen 1. <i>American Journal of Pathology</i> , 2004, 164, 1347-1359.	3.8	129
79	Heterogeneity of Ductular Reactions in Adult Rat and Human Liver Revealed by Novel Expression of Deleted in Malignant Brain Tumor 1. <i>American Journal of Pathology</i> , 2002, 161, 1187-1198.	3.8	64
80	E2F activity is essential for survival of Myc-overexpressing human cancer cells. <i>Oncogene</i> , 2002, 21, 6498-6509.	5.9	19
81	Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway. <i>Molecular and Cellular Biology</i> , 2000, 20, 3497-3509.	2.3	169
82	Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. <i>Nature</i> , 1999, 401, 815-818.	27.8	269
83	p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. <i>Oncogene</i> , 1999, 18, 3930-3935.	5.9	68
84	Acceleration of c-myc-Induced Hepatocarcinogenesis by Co-Expression of Transforming Growth Factor (TGF)- $\beta$ 1 in Transgenic Mice Is Associated with TGF- $\beta$ 1 Signaling Disruption. <i>American Journal of Pathology</i> , 1999, 154, 1693-1700.	3.8	52
85	Growth Inhibition and Induction of Apoptosis by HGF in Transformed Rat Liver Epithelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 236, 396-401.	2.1	36
86	Interaction of c-myc with transforming growth factor $\beta$ 1 and hepatocyte growth factor in hepatocarcinogenesis. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1997, 376, 221-234.	1.0	9
87	Hepatic Tumor Induction in c- Myc mono-transgenic and TGF- $\beta$ 1/c-Myc double-transgenic Mice. <i>Archives of Toxicology Supplement</i> , 1997, 19, 359-366.	0.7	6
88	Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 9577-9582.	7.1	112
89	In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. <i>Hepatology</i> , 1996, 23, 71-79.	7.3	76
90	Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor $\beta$ 1 and hepatocyte growth factor in hepatocarcinogenesis. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 43-52.	2.4	38

#	ARTICLE	IF	CITATIONS
91	Proliferation, apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. <i>Hepatology</i> , 1996, 23, 62-70.	7.3	9
92	Differential modulation of P-glycoprotein expression by dexamethasone and 3-methylcholanthrene in rat hepatocyte primary cultures. <i>Carcinogenesis</i> , 1994, 15, 335-341.	2.8	42
93	Assessment of P-glycoprotein-dependent drug transport in isolated rat hepatocytes using rhodamine 123. <i>Cell Biology and Toxicology</i> , 1993, 9, 235-241.	5.3	16
94	Inducibility of gamma-glutamyltransferase by dexamethasone in rat liver: Relationship with the cytochrome P-450 content. <i>Life Sciences</i> , 1993, 52, 631-637.	4.3	1
95	MicroRNAs as potential biomarkers in malignant pleural mesothelioma. <i>Current Biomarker Findings</i> , 0, 1.	0.4	0
96	Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma. <i>Precision Cancer Medicine</i> , 0, 2, 5-5.	1.8	1